Liangliang Qing1, Peng Gu1, Mingsheng Liu2, Jihong Shen1, Xiaodong Liu1, Runyun Guang1, Kunbin Ke1, Zhuo Huang1, Wenhui Lee1,3, Hui Zhao1. 1. Department of Urology, First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, People's Republic of China. 2. Second Ward of Urology, Qujing Affiliated Hospital of Kunming Medical University, Qujing, Yunnan, People's Republic of China. 3. Key Laboratory of Animal Models and Human Disease Mechanisms of Chinese Academy of Sciences, Kunming Institute of Zoology, Kunming, Yunnan, People's Republic of China.
Abstract
INTRODUCTION: Bladder cancer (BC) is the fourth-commones cancer and the sixth-leading cause of cancer-related death among men. However, a lack of reliable biomarkers remains a problem forprognosis and treatment of BC. lncRNAs have been shown to play important roles in various cancers, and have emerged as promising biomarkers for cancer prognosis and treatment. METHODS: In this study, using univariate and multivariate Cox regression analysis, we examined the differential expression profiles of 1,651 lncRNAs in the TCGA BLCA cohort and created a prognostic gene signature composed of six lncRNAs (for SNHG12, MAFG- DT, ASMTL-AS1, LINC02321, LINC01322, and LINC00922), designed the SMALLL signature. RESULTS: The SMALLL signature displayed significant prognostic power for overall survival for BC patients in multiple cohorts. Gene Ontology analysis showed that genes coexpressed with the SMALLL signature were associated with the extracellular matrix network, and immune cell-infiltration analysis showed that activated naïve B cells, regulatory T cells, M0 macrophages, eosinophils, resting memory CD4 T cells and resting NK cells were significantly different in high- and low-risk groups. We also confirmed differential expression of the lncRNAs of the SMALLL signature in BC tissue and paracancer normal tissue by qRT-PCR analysis. Cell-invasion and -migration experiments showed that MAFG-AS1, ASMTL-AS1, LINC02321, and LINC00922 significantly affected cell invasion and migration. CONCLUSION: Our study revealed that the lncRNA signature is an important predictive factor of prognosis and provides a promising biomarker for BC.
INTRODUCTION: Bladder cancer (BC) is the fourth-commones cancer and the sixth-leading cause of cancer-related death among men. However, a lack of reliable biomarkers remains a problem forprognosis and treatment of BC. lncRNAs have been shown to play important roles in various cancers, and have emerged as promising biomarkers for cancer prognosis and treatment. METHODS: In this study, using univariate and multivariate Cox regression analysis, we examined the differential expression profiles of 1,651 lncRNAs in the TCGA BLCA cohort and created a prognostic gene signature composed of six lncRNAs (for SNHG12, MAFG- DT, ASMTL-AS1, LINC02321, LINC01322, and LINC00922), designed the SMALLL signature. RESULTS: The SMALLL signature displayed significant prognostic power for overall survival for BC patients in multiple cohorts. Gene Ontology analysis showed that genes coexpressed with the SMALLL signature were associated with the extracellular matrix network, and immune cell-infiltration analysis showed that activated naïve B cells, regulatory T cells, M0 macrophages, eosinophils, resting memory CD4 T cells and resting NK cells were significantly different in high- and low-risk groups. We also confirmed differential expression of the lncRNAs of the SMALLL signature in BC tissue and paracancer normal tissue by qRT-PCR analysis. Cell-invasion and -migration experiments showed that MAFG-AS1, ASMTL-AS1, LINC02321, and LINC00922 significantly affected cell invasion and migration. CONCLUSION: Our study revealed that the lncRNA signature is an important predictive factor of prognosis and provides a promising biomarker for BC.
Authors: Timur Mitin; Daniel Hunt; William U Shipley; Donald S Kaufman; Robert Uzzo; Chin-Lee Wu; Mark K Buyyounouski; Howard Sandler; Anthony L Zietman Journal: Lancet Oncol Date: 2013-07-01 Impact factor: 41.316
Authors: Matthew T Witkowski; Igor Dolgalev; Nikki A Evensen; Chao Ma; Tiffany Chambers; Kathryn G Roberts; Sheetal Sreeram; Yuling Dai; Anastasia N Tikhonova; Audrey Lasry; Chunxu Qu; Deqing Pei; Cheng Cheng; Gabriel A Robbins; Joanna Pierro; Shanmugapriya Selvaraj; Valeria Mezzano; Marla Daves; Philip J Lupo; Michael E Scheurer; Cynthia A Loomis; Charles G Mullighan; Weiqiang Chen; Karen R Rabin; Aristotelis Tsirigos; William L Carroll; Iannis Aifantis Journal: Cancer Cell Date: 2020-05-28 Impact factor: 31.743